A multicenter phase II study of single-agent enzastaurin in previously treated Waldenström macroglobulinemia

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 5043-5050

  Ghobrial, Irene M ^a   Moreau, Philippe ^b   Harris, Brianna ^a   Poon, Tiffany ^a   Jourdan, Eric ^c   Maisonneuve, Hervé ^d   Benhadji, Karim A ^e   Hossain, Anwar M ^f   Nguyen, Tuan S ^f   Wooldridge, James E ^f   Leblond, Veronique ^g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITÉ DE NANTES   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d Centre territorial d'evaluation et de traitement de la douleur   (France)

^e Lilly France   (France)

^f ELI LILLY AND COMPANY   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; DEXAMETHASONE; ENZASTAURIN; FLUDARABINE; INTERLEUKIN 15; RITUXIMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DIZZINESS; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FLATULENCE; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; URINE COLOR; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN M; INDOLES; MALE; MIDDLE AGED; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84866392045     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0181     Document Type: Article

References (32)

1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5.
2. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113:4163-70.
3. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000;18:214-26.
4. Dimopoulos MA, Galani E, Matsouka C. Waldenström's macroglobulinemia. Hematol Oncol Clin North Am 1999;13:1351-66.
5. Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel SR, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:121-6.
6. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120-6.
7. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, et al. Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Res 2007;67:3777-84.
8. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72.
9. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-33.
10. Rajkumar SV, Hayman S, Greipp PR. Angiogenesis in Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:262-4.
11. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-69.
12. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9.
13. Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;20:1565-75.
14. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
15. Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53.
16. Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116-20.
17. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglubulinemia. Clin Lymphoma Myeloma 2006;6:380-3.
18. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. American Society of Clinical Oncology, American Society of Hematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
19. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-85.
20. Miller R, Siegmund D. Maximally selected chi-square statistics for small samples. Biometrics 1982;38:1011-6.
21. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655-8.
22. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570- 5.
23. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5.
24. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16:1033-41.
25. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-14.
26. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-55.
27. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenström Macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009;147:677-80.
28. Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011;86:573- 8.
29. Hainsworth JD, Arrowsmith E, McCleod L, Fayad L, Hamid O, Davis L, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): preliminary analysis. J Clin Oncol 2011;29:15(suppl): Abstract 8016.
30. + T cells. Proc Natl Acad Sci U S A 2004;101:1969-74.
31. + T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
32. ClinicalTrials.gov. A phase I study of intravenous recombinant human IL-15 in adults with refractory metastatic malignant melanoma and metastatic renal cell cancer. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01021059. Accessed 2011 Sept 30.